Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239943 | 0.90 | LMNA (0.44) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL1358172 | 0.90 | LMNA (0.44) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL1357148 | 0.90 | LMNA (0.45) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL12239928 | 0.89 | LMNA (0.44) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL18473879 | 0.88 | HPGD (0.45) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL1359711 | 0.87 | LMNA (0.43) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL21120818 | 0.87 | LMNA (0.44) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL12239941 | 0.85 | HPGD (0.44) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL16402271 | 0.83 | TSHR (0.46) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL1357442 | 0.82 | HTT (0.50) | HPGDLMNAALDH1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617194-B1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3617194-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV Healthcare Company (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-2376453-B1 | INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-2376080-B1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO (JP) | 2017-09-13 | — | — | EP | disclosed |
| EP-3210603-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO., LTD (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9365587-B2 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | SHIONOGI & CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160060274-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | VIIV HEALTHCARE COMPANY (US) | 2016-03-03 | — | — | US | disclosed |
| US-9242986-B2 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-8669362-B2 | Processes and Intermediates for carbamoylpyridone HIV integrase inhibitors | SHIONGI & CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8624023-B2 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20140005405-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE COMPANY (US) | 2014-01-02 | — | — | US | disclosed |
| US-8552187-B2 | Processes and intermediates for carbamoylpyridone HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2011-11-17 | — | — | US | disclosed |
| US-20110263855-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2376080-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | Shionogi&Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376453-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068262-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068253-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263855-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | INTS6, IDH1, OPRM1 | HPGD 1093/4885LMNA 3139/4885ALDH1A1 293/4885 |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | CYP3A5, CYP3A43, CYP3A4 | HPGD 706/4885LMNA 2611/4885ALDH1A1 1691/4885 |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | CDK2, CDK6, BRD4 | HPGD 1839/4885LMNA 2423/4885ALDH1A1 1510/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | HPGD 1115/4885LMNA 3050/4885ALDH1A1 1838/4885 |
| US-20140005405-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | INTS6, IDH1, OPRM1 | HPGD 832/4885LMNA 3599/4885ALDH1A1 224/4885 |
| US-20160060274-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | IL2, QPCT, IL4I1 | HPGD 1265/4885LMNA 1106/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.